[A21-89] Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2021
Commission awarded on 01.07.2021 by the Federal Joint Committee (G-BA).
First-line treatment of unresectable malignant pleural mesothelioma in adults
- Patients with epithelioid tumour histology: added benefit not proven.
- Patients with non-epithelioid tumour histology: indication of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.